Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/29/2015)... March 29, 2015  Caris Life Sciences® today ... Caris Molecular Intelligence®, the company,s panomic, comprehensive tumor ... between several rare and difficult to treat gynecological ... the potential to improve patient outcomes. These studies ... the Society of Gynecologic Oncology (SGO) 2015 Annual ...
    (Date:3/29/2015)... 2015 Caris Life Sciences® today ... showing the presence of PD-1 and PD-L1 ... Using Caris Molecular Intelligence®, the company,s panomic ... of programmed cell death protein-1 (PD-1) in ... its ligand (PD-L1) expression was variable across ...
    (Date:3/27/2015)... Earlier this year, the Capillus272Pro™ ... regrowth in adult men and women with androgenic alopecia ... classifications of IIa-V and Fitzpatrick Classification of Skin phototypes ... that over-promise and under-deliver, FDA Clearance underscores the safety ... among more than 80 million men and women who ...
    (Date:3/27/2015)... März 2015  Peter Walter wurde als ... für seine bahnbrechende Arbeit ausgewählt, die sich ... werden, sowie für die Entschlüsselung der Komponenten ... Stress nutzen, der mit der Ansammlung von ... für Biochemie an der University of California, ...
    Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
    ... ... received ANVISA approval to market the TriPollar Technology- the most advanced 3rd ... anti-aging products have been clinically proven the world over to be safe ... non-invasive and patients enjoy visible results from the very 1st treatment. ...
    ... , CORALVILLE, Iowa, Dec. 4 Vivakor, Inc. ... record on December 1, 2009 will receive the dividend of ... approved by Vivakor,s Board of Directors. HealthAmerica is a ... the outstanding common shares on the record date. The distribution ...
    ... , , MELVILLE, N.Y., Dec. ... instruments, announced today that it has signed a licensing ... use the Stochastic Optical Reconstruction Microscopy (STORM) technology. Under ... enabled microscopy systems and market them with the N-STORM ...
    Cached Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3
    (Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
    (Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
    (Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
    ... shows the Arctic climate system may be more sensitive to ... Earth,s atmospheric carbon dioxide may be high enough to bring ... the University of Colorado at Boulder, the international study indicated ... the High Arctic during the Pliocene Epoch 2.6 to 5.3 ...
    ... Society of America (ESA) will present seven societal awards ... August 1-6, 2010 in Pittsburgh. The meeting, which has ... the challenge for our future," draws a critical combination ... to explore the causes and consequences of global warming ...
    ... that, despite thousands of changes that viruses like HIV undergo ... original version that caused the infection is still present in ... June issue of the Journal of Virology , is ... action that takes place in an organism shortly after infection. ...
    Cached Biology News:Arctic climate may be more sensitive to warming than thought, says new study 2Arctic climate may be more sensitive to warming than thought, says new study 3Arctic climate may be more sensitive to warming than thought, says new study 4Ecological Society of America announces 2010 award recipients 2Ecological Society of America announces 2010 award recipients 3Ecological Society of America announces 2010 award recipients 4Despite countless changes, original HIV infection lurks within 2Despite countless changes, original HIV infection lurks within 3
    ... differences exist between the various commercial and ... slide used, the length and GC content ... the manufacturing protocol employed all influence the ... With all the different variables to ...
    ... Gel Stain combo offers these benefits: ... separately Offers a safer ... Eliminates risks to yourself, the environment and ... 100 bp to >30 kb. UltraPure Agarose is a ...
    This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
    ... contains 400 unique human proteins on ... The proteins, all extracellular proteins (EP) ... arrayed in quadruplicate for high-quality results. ... chip layout guarantee high validity and ...
    Biology Products: